Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review

Background: Obesity is a chronic disease, which along with its complications, poses a huge threat to both our health as individuals and our healthcare as a community. Objective: The aim of this work is to review efficacy and safety of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist in the t...

Full description

Bibliographic Details
Main Authors:	Bartłomiej Stachyra, Marta Wolanin, Cezary Stawikowski, Bartłomiej Zielonka, Aleksandra Osińska, Izabela Wolanin, Karolina Madej, Barbara Dengler, Ilona Kowalczyk, Paulina Krawiec
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2023-04-01
Series:	Journal of Education, Health and Sport
Subjects:	tirzepatide obesity obesity treatment anti-obesity drug glucose-dependent insulinotropic polypeptide glucagon-like peptide 1
Online Access:	https://apcz.umk.pl/JEHS/article/view/43077

Similar Items

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
by: Rouchan Ali, et al.
Published: (2022-09-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
by: Zhuqing Meng, et al.
Published: (2023-03-01)

Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent
by: ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia
Published: (2023-05-01)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
by: Rachel Sinha, et al.
Published: (2023-03-01)

Tirzepatide-induced ketoacidosis in non-diabetic patients
by: Pathan Mohamad Rafe Iqbal, et al.
Published: (2024-03-01)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
by: Razzaki TS, et al.
Published: (2022-09-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
by: Baptist Gallwitz
Published: (2022-10-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
by: Nicholas Chiu, et al.
Published: (2022-08-01)

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
by: Shu-Chen Lu, et al.
Published: (2021-05-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
by: Alessia Costa, et al.
Published: (2022-01-01)

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023-01-01)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
by: Alekya Devi Anala, et al.
Published: (2023-07-01)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022-05-01)

Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
by: Wenting Cai, et al.
Published: (2024-01-01)

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
by: Vivek P. Chavda, et al.
Published: (2022-07-01)

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women
by: Sonya Vasto, et al.
Published: (2022-02-01)

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
by: Pejman Rohani, et al.
Published: (2023-08-01)

Peripartum cardiomyopathy: current theories about etiopathogenesis, potential biomarkers and treatment - a literature review
by: Bartłomiej Zielonka, et al.
Published: (2023-06-01)

Transcranial magnetic stimulation as a promising method of treatment in depression and various neuropsychiatric conditions. A literature review
by: Ilona Kowalczyk, et al.
Published: (2023-08-01)

Multifaceted therapeutic options for stress urinary incontinence in women
by: Aleksandra Osińska, et al.
Published: (2023-04-01)

Diabetics suffer in silence – about sexual dysfunction and modern therapeutic possibilities in diabetes mellitus
by: Karolina Madej, et al.
Published: (2023-04-01)

Inclisiran - hope in the fight against dyslipidemia
by: Paulina Krawiec, et al.
Published: (2023-05-01)

Pancreatic Islet Transplantation in Patients suffering from Type 1 diabetes - Indications, methods, possible risks and future directions: A literature review
by: Marta Wolanin, et al.
Published: (2023-05-01)

Do the benefits outweigh the risks? Potential dangers associated with long-term therapy of proton pump inhibitors
by: Wolanin Wolanin, et al.
Published: (2023-05-01)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
by: Sara Baldassano, et al.
Published: (2019-08-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
by: Donna H. Ryan
Published: (2021-09-01)

Sudden infant death syndrome (SIDS) - How to reduce the risk?
by: Barbara Dengler, et al.
Published: (2023-05-01)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
by: Qingyue Zeng, et al.
Published: (2023-10-01)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
by: Giuseppe Lisco, et al.
Published: (2022-09-01)

Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
by: Qingyue Zeng, et al.
Published: (2024-03-01)